Cisplatin-albumin complex for treatment of cancer of the head and neck.
Many patients with cancer of the head and neck are unable to receive or continue treatment with cisplatin, which is nephrotoxic, because of poor renal function. We present here, however, the case of a patient who underwent conventional cisplatin therapy but who then had to be withdrawn from treatment because of renal toxicity despite having undergone partial remission. Treatment was then changed to cisplatin in the form of a cisplatin-albumin complex which is not nephrotoxic. The patient went on to a histologically confirmed complete response and we suggest that although the cisplatin-albumin complex may not be as effective as the conventional form of the drug it offers a possible form of treatment of patients with compromised renal function who could not otherwise be treated.
Vreeburg
G C
GC
Department of Otorhinolaryngology, University of Liverpool.
Stell
P M
PM
Holding
J D
JD
Lindup
W E
WE
D000368:Aged; D000418:Albumins / Q000008:administration & dosage*; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced; D007822:Laryngeal Neoplasms / Q000188:drug therapy*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*
D000418:Albumins; D004338:Drug Combinations; D002945:Cisplatin